Logo
Logo

About Sumatriptan Succinate API

Product
  • Therapeutic CategoryPain Management

  • CAS Number

    103628-48-4

  • API Technology

    Synthetic

  • Dose Form

    Injectable

  • Dr Reddy's Development Status

    Available

  • Available Regulatory Filing

    USDMF, CEP Submitted, Brazil DMF, EUDMF, Japan DMF, Russia DMF

Mechanism of Action

Sumatriptan binds with high affinity to human cloned 5-HT1B/1D receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine headache through agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.

Indication

ZEMBRACE SymTouch is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for:

  • Acute treatment of migraine with or without aura in adults Limitations of Use:
  • Use only if a clear diagnosis of migraine has been established.
  • Not indicated for the prophylactic therapy of migraine.

Related APIs

萘普生

Pain Management

arrow

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone
Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.